TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04857931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
Study: NCT06525324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant surgery with T-PRF and xenograft
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with T-PRF and xenograft will be placed according to the standard protocol.~The surgical wound closure will be coapted with mattress and single interrupted sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant surgery with PRF and xenograft
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with PRF and xenograft will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures
Study: NCT05668962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Selpercatinib Oral, twice daily during initial treatment period (28 Days). A second course of selpercatinib if the participant is demonstrating clinical benefit to the initial course selpercatinib and deemed clinically appropriate by the treating investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Iodine I-131
Description: I-131 NaI, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: RhTSH injection, dosage per protocol, timing per protocol during the initial treatment period per standard of care.~Participants may receive a second course of rhTSH if the participant is demonstrating clinical benefit to the initial course rhTSH and deemed clinically appropriate by the treating investigator.
Study: NCT06195540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb.~Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment).~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Heparin Molecular Weight
Description: Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician.
Study: NCT05905926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study. Doses can be titrated to either 50 mg BID or 25 mg BID
Study: NCT05451654

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
Study: NCT05952180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality and Cycloergometer
Description: The session performed uses a standard cycloergometer, with the participant pedaling in a seated position with the lower limbs. A 43 inches TV screen is placed in front of the cycloergometer where the participant will watch a video of a walk through a natural environment on. The speed of the walk is linked to the pedaling speed so that the faster the participant pedals, the faster the video goes too. The session last 30 minutes in the participant's room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard cycloergometer
Description: the session uses usual cycloergometer with the participant pedaling in a seated position with the lower limbs. The session lats 30 minutes in the participant's room.
Study: NCT04777500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous electrical nerve stimulation device
Description: We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous electrical nerve stimulation device
Description: We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.
Study: NCT05271864

Intervention type: DEVICE
Intervention: Apple Watch
Description: Apple Watch

Intervention type: DEVICE
Intervention: Apple Watch
Description: Apple Watch

Intervention type: DEVICE
Intervention: Apple Watch
Description: Apple Watch
Study: NCT06440291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: Cardioneuroablation procedure performed according to the protocol
Study: NCT05682053

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multiparametic MRI
Description: patients will have a Multiparametric MRI

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multiparametic MRI
Description: patients will have a Multiparametric MRI
Study: NCT04530890

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Only blood samples at different times of treatment
Study: NCT06579508

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cycle ergometer
Description: The initial part will last 5 minutes at low intensity, corresponding to easy by the RPE.~The main part will be performed at the intensity of training zone 3 (100-110% of the Lan), lasting 5 minutes with a rest of 2.5 minutes between exercises. The intensity will be controlled by HR and RPE.~The final part will last 3 minutes at low intensity, corresponding to easy by the RPE.~The load progression occurred during the first four weeks, starting with 3 sets and adding 1 set per week.~The intensity of each effort is 100-110%HRAnTh.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Description: The initial part will last 5 minutes at low intensity, corresponding to easy by the RPE.~The main part will be performed at the intensity of training zone 3 (100-110% of the Lan), lasting 5 minutes with a rest of 2.5 minutes between exercises. The intensity will be controlled by HR and RPE.~The final part will last 3 minutes at low intensity, corresponding to easy by the RPE.~The load progression occurred during the first four weeks, starting with 3 sets and adding 1 set per week.~The intensity of each effort is 100-110%HRAnTh.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cycle ergometer
Description: The initial part will last 5 minutes at low intensity, corresponding to easy by the RPE.~The main part will be performed at the intensity of training zone 3 (100-110% of the Lan), lasting 5 minutes with a rest of 2.5 minutes between exercises. The intensity will be controlled by HR and RPE.~The final part will last 3 minutes at low intensity, corresponding to easy by the RPE.~The load progression occurred during the first four weeks, starting with 3 sets and adding 1 set per week.~The intensity of each effort is 100-110%HRAnTh.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cycle ergometer
Description: The initial part will last 5 minutes at low intensity, corresponding to easy by the RPE.~The main part will be performed at the intensity of training zone 3 (100-110% of the Lan), lasting 5 minutes with a rest of 2.5 minutes between exercises. The intensity will be controlled by HR and RPE.~The final part will last 3 minutes at low intensity, corresponding to easy by the RPE.~The load progression occurred during the first four weeks, starting with 3 sets and adding 1 set per week.~The intensity of each effort is 100-110%HRAnTh.
Study: NCT06580457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Causal Model + Personalized Feedback
Description: Receive a personal causal model of one's personalized causes of substance use/urges, along with a 1-hour, live clinical feedback session to suggest how to apply these insights to one's own recovery.
Study: NCT06579807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The multimodal supervised exercise program will include aerobic, resistance, and flexibility exercises. The training program will last 12 weeks, performed in 3 weekly sessions lasting 60 minutes each. Aerobic exercise, lasting between 20-30 minutes, will be conducted on a treadmill or stationary bike at an intensity ranging from 75-85% of the maximal heart rate (HR), based on the cardiopulmonary exercise testing. Resistance training, lasting 30 minutes, will include 8 to 10 exercises performed in 3 sets of 10 to 12 maximum repetitions with 1-minute intervals, targeting major muscle groups of the upper and lower limbs, with loads corresponding to 80-90% of the 10-repetitions maximum (RM).
Study: NCT05962788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voclosporin
Description: Subjects will receive 2 capsules (15.8 mg) BID (twice daily), 3 capsules (23.7 mg) BID or 4 capsules (31.6 mg) BID of voclosporin in addition to standard of care with mycophenolate mofetil (MMF) and steroids.
Study: NCT05441085

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: programed intermittent epidural bolus interval 90 (EI90)
Description: programed intermittent epidural bolus interval 90 (EI90) of 10 ml, 0.0625% bupivacaine plus 2 μg/mL fentanyl

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: programed intermittent epidural bolus interval 90 (EI90)
Description: programed intermittent epidural bolus interval 90 (EI90) of 10 ml, 0.0625% bupivacaine plus 2 μg/mL fentanyl
Study: NCT05222815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM
Description: Continuous glucose monitor (CGM)-based glucose monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG
Description: Self-monitoring of blood glucose (SMBG)-based glucose monitoring
Study: NCT05581186

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulse electromagnetic field therapy
Description: It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 25 Hz frequency, 30 Gauss, %35 intensity and for 25 minutes. The treatment period was 5 days a week for 3 weeks, in total. It was applied as 15 sessions.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham pulse electromagnetic field therapy
Description: Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 15 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
Study: NCT05131880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GAIT RE-EDUCATION PROGRAM ON A SEQUENTIAL MAT IN SUBJECTS WITH PARKINSON'S DISEASE
Description: Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GAIT RE-EDUCATION PROGRAM ON A SEQUENTIAL MAT IN SUBJECTS WITH PARKINSON'S DISEASE
Description: Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition.
Study: NCT05581186

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Exercise
Description: Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
Study: NCT05362890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEVICE OPERATING UNDER THE CONTINOUS POSITIVE AIRWAY PRESSURE
Description: The principle of operation is to prevent the closure and the narrowing of the structures of the upper respiratory tract by applying positive pressure. The device consists of a mask that protects the nose and/or mouth, a tube that connects the mask to the monitor and a monitor that blows air into the tube. A pressure in the range of 4 to 20 cm water is applied, depending on the individual needs of the patient to keep the airway open. The use is considered to be effective when the patient uses it continuously for at least 4 hours at bedtime. Today's modern devices have memory cards for storing data on the regularity and time of use of the device during the night and the efficiency of the device itself. For therapy to be considered effective, the number of apneas and hypopneas must be less than 5 per hour of sleep.
Study: NCT05781659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound elastography guided pleural biopsy
Description: The patients will undergo ultrasound elastography (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional ultrasound guided pleural biopsy
Description: The patients will undergo traditional ultrasound (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
Study: NCT05801211

Intervention type: PROCEDURE
Intervention: primary tumor resection
Description: primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)
Study: NCT04139564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx headset
Description: EaseVRx is a virtual reality therapy intended to treat chronic pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active control VR sham program
Description: VR, 2d visual wildlife scenes similar to some EaseVRx content
Study: NCT05029375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS® for Preschoolers
Description: P4P is a 16-week manualized social skills treatment program, adapted from an existing empirically supported social skills intervention for young children with autism

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS® for Preschoolers
Description: P4P is a 16-week manualized social skills treatment program, adapted from an existing empirically supported social skills intervention for young children with autism
Study: NCT04767789

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NZ-GHMH-01
Description: Each randomized subject will consume 1 capsule daily bringing 100 mg (≥ 2 x 109 CFU) of active ingredient during 16 weeks (from V2 to V5 visits).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each randomized subject will consume 1 capsule with no active ingredient daily during 16 weeks (from V2 to V5 visits).
Study: NCT06050850

Intervention type: BEHAVIORAL
Intervention: NOURISH-ALL
Description: Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.

Intervention type: BEHAVIORAL
Intervention: NOURISH-ALL
Description: Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.
Study: NCT06386588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed loop auditory stimulation during sleep
Description: Short bursts of pink noise delivered at precise times during overnight sleep at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed loop auditory stimulation during sleep
Description: Short bursts of pink noise delivered at precise times during overnight sleep at home.
Study: NCT06485817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.
Study: NCT04549792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Each subject will receive ustekinumab at Baseline (Day 0) and Months 1, 3, 5, 7, 9, and 11. During the LTE, subjects will receive injections every 8 weeks for one year: Month 13, Month 15, Month 17, Month 19, Month 21, and Month 23. Subjects will come back in for a follow-up visit at Month 25 for an end of study visit (no drug administration).
Study: NCT05362877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Earplug
Description: Using earplugs to reduce the symptoms of temporomandibular disorder

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Earplug
Description: Using earplugs to reduce the symptoms of temporomandibular disorder

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Earplug
Description: Using earplugs to reduce the symptoms of temporomandibular disorder

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusal splint
Description: Using occlusal splints to reduce the symptoms of temporomandibular disorder

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusal splint
Description: Using occlusal splints to reduce the symptoms of temporomandibular disorder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Applying exercise to reduce the symptoms of temporomandibular disorder